| trastuzumab based treatment |
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel |
| es-BC - HER2 positive - (neo)adjuvant (NA) 4 | |
Comparator:
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel;
Risk of bias:
low;
some concerns;
high;
NA;